Acorda Therapeutics PT Raised to $50.00 at Aegis (ACOR)
Stock analysts at Aegis lifted their target price on shares of Acorda Therapeutics (NASDAQ:ACOR) from $43.00 to $50.00 in a report issued on Tuesday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Aegis’ price target suggests a potential upside of 46.20% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research note to investors on Friday, September 6th. They now have a $38.00 price target on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Acorda Therapeutics (NASDAQ:ACOR) from $37.73 to $50.00 in a research note to investors on Friday, August 2nd. Finally, analysts at Feltl & Co. raised their price target on shares of Acorda Therapeutics (NASDAQ:ACOR) from $40.00 to $43.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $42.67.
Acorda Therapeutics (NASDAQ:ACOR) traded up 1.20% during mid-day trading on Tuesday, hitting $34.61. 54,463 shares of the company’s stock traded hands. Acorda Therapeutics has a 52 week low of $22.37 and a 52 week high of $40.87. The stock has a 50-day moving average of $35.10 and a 200-day moving average of $34.7. The company has a market cap of $1.385 billion and a P/E ratio of 9.62.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Thursday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.16. The company had revenue of $87.05 million for the quarter, compared to the consensus estimate of $82.57 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. On average, analysts predict that Acorda Therapeutics will post $0.27 earnings per share for the current fiscal year.
Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.